Literature DB >> 20463489

Assessing jaundice in infants of 35-week gestation and greater.

Meredith Lease1, Bonny Whalen.   

Abstract

PURPOSE OF REVIEW: In 2004, the American Academy of Pediatrics officially recommended universal predischarge risk assessment for severe neonatal hyperbilirubinemia with the goal of minimizing subsequent risk of chronic bilirubin encephalopathy (formerly known as kernicterus). In this article, we review recent research regarding jaundice predischarge risk assessment, current expert recommendations for universal predischarge bilirubin screening, and concerns expressed in the literature regarding these recommendations. RECENT
FINDINGS: A group of experts have recently recommended universal predischarge bilirubin screening to identify newborns at risk for developing severe neonatal hyperbilirubinemia. In contrast, the United States Preventive Services Task Force states that there is insufficient evidence to make this recommendation. Transcutaneous bilirubinometry has emerged as a noninvasive, quick method to screen for neonatal hyperbilirubinemia, although refinement and validation of transcutaneous bilirubin nomograms are needed. Newer studies suggest that the combined use of a predischarge bilirubin and gestational age risk assessment offers a simple, objective, and accurate way to identify infants at risk for subsequent, severe hyperbilirubinemia.
SUMMARY: All newborns should be systematically assessed for risk of developing severe hyperbilirubinemia prior to hospital discharge. Although limited data exist to recommend its use universally, predischarge bilirubin screening should be considered given recent expert opinion. The role of transcutaneous bilirubinometry remains promising, although further research evaluating and validating its use in varied and diverse populations is imperative. Combined models of risk assessment may offer the best approach to identifying infants at risk for subsequent, severe hyperbilirubinemia.

Entities:  

Mesh:

Year:  2010        PMID: 20463489     DOI: 10.1097/MOP.0b013e328339603f

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  5 in total

1.  Sixth hour transcutaneous bilirubin predicting significant hyperbilirubinemia in ABO incompatible neonates.

Authors:  Ramesh Y Bhat; Pavan C G Kumar
Journal:  World J Pediatr       Date:  2013-06-17       Impact factor: 2.764

2.  Neonatal cholestasis: opportunities to increase early detection.

Authors:  Joseph J Palermo; Shannon Joerger; Yumirle Turmelle; Peter Putnam; Jane Garbutt
Journal:  Acad Pediatr       Date:  2012-05-26       Impact factor: 3.107

3.  Screening and treatment to reduce severe hyperbilirubinaemia in infants in primary care (STARSHIP): a factorial stepped-wedge cluster randomised controlled trial protocol.

Authors:  Berthe A M van der Geest; Johanna P de Graaf; Loes C M Bertens; Marten J Poley; Erwin Ista; René F Kornelisse; Irwin K M Reiss; Eric A P Steegers; Jasper V Been
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

4.  Assessing knowledge and skills of maternity care professionals regarding neonatal hyperbilirubinaemia: a nationwide survey.

Authors:  Berthe A M van der Geest; Imke M Theeuwen; Irwin K M Reiss; Eric A P Steegers; Jasper V Been
Journal:  BMC Pregnancy Childbirth       Date:  2021-01-19       Impact factor: 3.007

5.  Assessment, management, and incidence of neonatal jaundice in healthy neonates cared for in primary care: a prospective cohort study.

Authors:  Berthe A M van der Geest; Malou J S de Mol; Ivana S A Barendse; Johanna P de Graaf; Loes C M Bertens; Marten J Poley; Erwin Ista; René F Kornelisse; Irwin K M Reiss; Eric A P Steegers; Jasper V Been
Journal:  Sci Rep       Date:  2022-08-23       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.